Kymera Therapeutics(KYMR)
$115.31-4.08 (-3.42%)
KYMR
Kymera Therapeutics financials statements
$115.31
At close:-4.08 (-3.42%)
Want to see KYMR full AI Analyst Report?
Kymera Therapeutics (KYMR) Ratios
455 Followers
Kymera Therapeutics Ratios
KYMR's free cash flow for Q3 2026 was $-78.23M. For the 2026 fiscal year, KYMR's free cash flow was decreased by $-315.00K and operating cash flow was $-77.91M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 10.47 | 7.53 | 4.73 | 5.88 | 4.88 |
| Quick Ratio | 10.47 | 7.53 | 4.73 | 5.88 | 4.88 |
| Cash Ratio | 4.29 | 1.77 | 1.28 | 0.96 | 0.52 |
| Solvency Ratio | -1.86 | -1.52 | -0.79 | -1.34 | -0.67 |
| Operating Cash Flow Ratio | -2.80 | -2.87 | -1.20 | -2.15 | -1.39 |
| Short-Term Operating Cash Flow Coverage | -16.93 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 708.07M | $ 367.85M | $ 224.53M | $ 306.43M | $ 305.01M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.05 | 0.09 | 0.15 | 0.03 | 0.03 |
| Debt-to-Equity Ratio | 0.05 | 0.11 | 0.21 | 0.04 | 0.04 |
| Debt-to-Capital Ratio | 0.05 | 0.10 | 0.18 | 0.03 | 0.04 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.10 | 1.17 | 1.46 | 1.23 | 1.32 |
| Debt Service Coverage Ratio | -21.64 | -868.42 | -730.62 | -861.68 | -557.97 |
| Interest Coverage Ratio | -1403.21 | -1050.74 | -844.54 | -916.23 | -574.46 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.98 | 1.17 | 1.45 | 0.32 | 0.38 |
| Net Debt to EBITDA | 0.91 | 0.15 | 0.18 | 0.34 | 0.31 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | -794.32% | -475.04% | -186.74% | -330.23% | -137.36% |
| EBITDA Margin | -773.11% | -459.37% | -182.21% | -323.87% | -134.07% |
| Operating Profit Margin | -891.33% | -555.82% | -210.62% | -344.37% | -138.03% |
| Pretax Profit Margin | -794.96% | -475.57% | -186.99% | -330.60% | -137.60% |
| Net Profit Margin | -794.39% | -475.57% | -186.99% | -330.60% | -137.60% |
| Continuous Operations Profit Margin | -794.96% | -475.57% | -186.99% | -330.60% | -137.60% |
| Net Income Per EBT | 99.93% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 89.19% | 85.56% | 88.78% | 96.00% | 99.69% |
| Return on Assets (ROA) | -17.87% | -22.89% | -25.52% | -25.67% | -16.54% |
| Return on Equity (ROE) | -19.71% | -26.79% | -37.21% | -31.58% | -21.80% |
| Return on Capital Employed (ROCE) | -21.05% | -28.74% | -33.78% | -30.32% | -19.58% |
| Return on Invested Capital (ROIC) | -20.88% | -28.33% | -33.35% | -30.10% | -19.45% |
| Return on Tangible Assets | -17.87% | -22.89% | -25.52% | -25.67% | -16.54% |
| Earnings Yield | -4.74% | -7.41% | -9.89% | -11.50% | -3.29% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 49.71 | 4.19 | 18.46 | 539.50 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.46 | 0.48 | 0.78 | 2.11 | 3.42 |
| Asset Turnover | 0.02 | 0.05 | 0.14 | 0.08 | 0.12 |
| Working Capital Turnover Ratio | 0.06 | 0.12 | 0.24 | 0.13 | 0.26 |
| Cash Conversion Cycle | 0.00 | 7.34 | 87.14 | 19.78 | 0.68 |
| Days of Sales Outstanding | 0.00 | 7.34 | 87.14 | 19.78 | 0.68 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 7.34 | 87.14 | 19.78 | 0.68 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.76 | -2.59 | -1.76 | -2.84 | -2.69 |
| Free Cash Flow Per Share | -2.78 | -2.76 | -2.35 | -2.89 | -2.72 |
| Dividend Paid and CapEx Coverage Ratio | -160.73 | -15.15 | -2.98 | -53.98 | -80.74 |
| Capital Expenditure Coverage Ratio | -160.73 | -15.15 | -2.98 | -53.98 | -80.74 |
| Operating Cash Flow Coverage Ratio | -2.83 | -2.22 | -1.21 | -8.83 | -7.18 |
| Operating Cash Flow to Sales Ratio | -5.94 | -4.13 | -1.31 | -3.27 | -1.77 |
| Free Cash Flow Yield | -3.57% | -6.87% | -9.24% | -11.58% | -4.28% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -21.09 | -13.50 | -10.11 | -8.70 | -30.40 |
| Price-to-Sales (P/S) Ratio | 167.51 | 64.14 | 18.91 | 28.75 | 41.83 |
| Price-to-Book (P/B) Ratio | 4.16 | 3.61 | 3.76 | 2.75 | 6.63 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -28.02 | -14.56 | -10.82 | -8.63 | -23.34 |
| Price-to-Operating Cash Flow Ratio | -28.20 | -15.52 | -14.45 | -8.79 | -23.63 |
| Price-to-Earnings Growth (PEG) Ratio | -0.89 | -0.74 | 0.83 | -0.23 | -0.27 |
| Enterprise Value Multiple | -20.76 | -13.81 | -10.20 | -8.54 | -30.90 |
| Enterprise Value | 6.29B | 2.99B | 1.46B | 1.30B | 3.02B |
| EV to EBITDA | -20.76 | -13.81 | -10.20 | -8.54 | -30.90 |
| EV to Sales | 160.50 | 63.45 | 18.59 | 27.66 | 41.42 |
| EV to Free Cash Flow | -26.85 | -14.40 | -10.64 | -8.31 | -23.11 |
| EV to Operating Cash Flow | -27.02 | -15.35 | -14.21 | -8.46 | -23.40 |
| Tangible Book Value Per Share | 18.72 | 11.14 | 6.77 | 9.09 | 9.58 |
| Shareholders’ Equity Per Share | 18.72 | 11.14 | 6.77 | 9.09 | 9.58 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.46 | 0.63 | 1.35 | 0.87 | 1.52 |
| Net Income Per Share | -3.69 | -2.98 | -2.52 | -2.87 | -2.09 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 8.08 | 5.10 | 2.41 | 3.51 | 1.88 |
| SG&A to Revenue | 1.74 | 1.35 | 0.70 | 0.94 | 0.50 |
| Stock-Based Compensation to Revenue | 1.53 | 1.17 | 0.55 | 0.76 | 0.34 |
| Income Quality | 0.75 | 0.87 | 0.70 | 0.99 | 1.29 |
Currency in USD

